Anti-TAK1 (Ab-184) antibody
Specifications
| Product Cat#: | AB-07-3838 |
| Product type: | Primary antibody |
| Antigen: | TAK1 (Ab-184) |
| Immunogen: | A synthetic peptide derived from human TAK1 around the phosphorylation site of threonine 184 (I-Q-TP-H-M). The exact amino-acid sequence is proprietary. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:500~1:3000); ELISA (1:1000) |
| Reactivity: | Human, Mouse, Rat |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | PBS (without Mg2+ and Ca2+ ), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol |
| Concentration: | 1 mg/ml |
| Purity: | Antigen affinity chromatography |
| Storage: | Aliquot and freeze at -20°C. Avoid multiple freeze/thaw cycles. |
| Alternative names: | EC 2.7.11.25, M3K7, MAP3K7, Mitogen-activated protein kinase kinase kinase 7, TGF-beta- activated kinase 1, Transforming growth factor-beta-activated kinase 1, kinase TAK1 |
Target information
Orphan nuclear receptor that can act as a repressor or activator of transcription. An important repressor of nuclear receptor signaling pathways such as retinoic acid receptor, retinoid X, vitamin D3 receptor, thyroid hormone receptor and estrogen receptor pathways. May regulate gene expression during the late phase of spermatogenesis. Together with NR2C1, forms the core of the DRED (direct repeat erythroid-definitive) complex that represses embryonic and fetal globin transcription including that of GATA1. Binds to hormone response elements (HREs) consisting of two 5′-AGGTCA-3′ half site direct repeat consensus sequences. Plays a fundamental role in early embryonic development and embryonic stem cells. Required for normal spermatogenesis and cerebellum development. Appears to be important for neurodevelopmentally regulated behavior (By similarity). Activates transcriptional activity of LHCG. Antagonist of PPARA-mediated transactivation.
Provider
Erpantech Laboratory
